Women who have advanced recurrent ovarian cancer, specifically high-grade serious ovarian cancer that is platinum resistant. The treatment will consist of two treatment groups:
Subjects will be randomized into 1 of the 2 treatment groups:
Participants must meet the following criteria to be eligible for the trial:
If you've answered yes to all of the above questions, please
Email: [email protected] or Call: (310) 794-9728
Once in the study, participants will be randomized to one of the two treatment groups. You will receive Paclitaxel (PAC) and either a dose of AVB-S6-500 or placebo (inactive solution such as normal saline). You have a 50/50 chance of receiving AVB-S6-500 + PAC or placebo + PAC therefore, you will still be receiving standard of care treatment.
Since this is a “double-blind” study, neither you nor your study doctor and study staff will know whether you received AVB-S6-500 or placebo. This means that the study treatment will not be your study doctor’s choice but will be assigned randomly (like flipping a coin to decide which treatment you receive). You will receive the same study treatment throughout the study. All subjects have the right to withdraw from the study at any time, for any reason.
All participants enrolled in the study will undergo the following testing:
UCLA Protocol ID: GOG 3059 | AVB500-OC-004